A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- USA001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index between 18.0 and 32.0 kilograms per square meter (kg/m^2), inclusive, at screening.
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening and check-in as assessed by the investigator (or designee).
Exclusion Criteria:
- Positive hepatitis panel and/or positive human immunodeficiency virus test. Results consistent with previous vaccination to Hepatitis B are not exclusionary.
- Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing.
- Poor peripheral venous access.
- Have previously completed or withdrawn from this study or any other study investigating brensocatib, and have previously received brensocatib. Known allergy to brensocatib or any of the excipients used in the formulation.
- Exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
- Participated in more than 3 radiolabeled drug studies in the last 12 months (previous study to be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator).
Note: Other inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: [14C]-brensocatib
Healthy participants will receive single oral dose of [14C]-brensocatib on Day 1 under fasted conditions.
|
Oral solution.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Concentration Time Curve (AUC) of Brensocatib in Plasma
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pharmacokinetics of brensocatib following a single dose in healthy participants will be assessed.
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
|
AUC∞ Plasma Brensocatib/Plasma Total Radioactivity Ratio Calculated as AUC∞ of Plasma Brensocatib Relative to AUC∞ of Plasma Total Radioactivity
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
|
|
AUC∞ Blood/Plasma Total Radioactivity Ratio Calculated as AUC∞ of Whole Blood Total Radioactivity to AUC∞ of Plasma Total Radioactivity
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
|
|
Amount Excreted in Urine (Aeu) of Brensocatib
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
|
|
Total Radioactivity Expressed as Amount of [14C]-brensocatib Excreted in Urine
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
|
|
Total Radioactivity Expressed as Amount of [14C]-brensocatib Excreted in Feces (Aef)
Time Frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC of Brensocatib Metabolites in Plasma
Time Frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 9
|
Pharmacokinetics of the metabolites following a single dose of brensocatib in healthy participants will be assessed.
|
Pre-dose and at multiple timepoints post-dose on Days 1 to 9
|
|
Number of Participants Who Experienced at Least one Adverse Event (AE)
Time Frame: Up to Day 14
|
Safety and tolerability of a single dose of brensocatib will be determined in healthy participants.
|
Up to Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- INS1007-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.